AngioDynamics Inc ANGO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
AngioDynamics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AngioDynamics to Participate in Upcoming Investor Conferences
AngioDynamics Announces Publication of DIRECT Study Results and New Category I CPT Code for Pancreatic IRE
AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife® IRE for Prostate and Liver Cancer
AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability
AngioDynamics Announces Appointment of Eric Honroth as President and Chief Executive Officer
AngioDynamics and The PERT Consortium® Name Jacobi Hospital as ALPHA-PE Research Fund Award Recipient to Advance Real-World Pulmonary Embolism Evidence
AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026
Trading Information
- Previous Close Price
- $11.99
- Day Range
- $11.71–11.99
- 52-Week Range
- $9.40–16.29
- Bid/Ask
- $11.61 / $11.76
- Shares Outstanding
- 42.05M
- Market Cap
- $495.61M
- Volume/Avg
- 19,448 / 639,675
Key Statistics
- Price/Earnings (Normalized)
- 1,198.50
- Price/Sales
- 1.54
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
AngioDynamics Inc is a dynamic, diversified medical technology company committed to expanding treatment options and improving patient outcomes and quality of life by designing, manufacturing, and selling products and technologies that aid clinicians in the treatment of patients with cardiovascular disease and cancer diagnoses. The company's execution plan is built on R&D, clinical and regulatory pathway expansion, and customer-centric sales performance. The company's product offerings fall within two segments, Med Tech and Med Device. Med Tech includes Auryon and Thrombectomy, while Med Device has Peripheral Products (Interventional Devices), Ports, and Microwave Ablation. Geographically operates in the USA and Other countries; maximum revenue from the USA.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Stock Style Box
- Small Core
- Total Number of Employees
- 632
Valuation
Metric | ANGO |
|---|---|
Price/Earnings (Normalized) | 1,198.50 |
Price/Book Value | 3.10 |
Price/Sales | 1.54 |
Price/Cash Flow | 64.65 |
Price/Earnings
ANGO
Financial Strength
Metric | ANGO |
|---|---|
Quick Ratio | 1.32 |
Current Ratio | 2.40 |
Interest Coverage | −84.53 |
Quick Ratio
ANGO
Profitability
Metric | ANGO |
|---|---|
Return on Assets (Normalized) | −1.47% |
Return on Equity (Normalized) | −2.22% |
Return on Invested Capital (Normalized) | −2.04% |
Return on Assets
ANGO
Medical Instruments & Supplies Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Intuitive Surgical Inc ISRG | LOCK|Y?dtq#&G | LOCK|fk | $152B | |||
| Becton Dickinson & Co BDX | LOCK|M$ | LOCK|jGxr | $59B | |||
| Medline Inc Ordinary Shares - Class A MDLN | LOCK|&Dk?gv# | LOCK|CKn?> | $35B | |||
| Alcon Inc ALC | LOCK|BP##Fc^ | LOCK|>B@K@ | $35B | |||
| ResMed Inc RMD | LOCK|%$yMBHY | LOCK|P!@z! | $34B | |||
| West Pharmaceutical Services Inc WST | LOCK|^?&@?&$@ | LOCK|%> | $29B | |||
| Solventum Corp SOLV | LOCK|>JLYs?f | LOCK|<x | $15B | |||
| Baxter International Inc BAX | LOCK|bm | LOCK|!G?L> | $13B | |||
| The Cooper Companies Inc COO | LOCK|ntP@xk | LOCK|$V!&V | $12B | |||
| Align Technology Inc ALGN | LOCK|<@RYV! | LOCK|&vpD | $12B |
United States